

# Axial Spondyloarthritis: Disease State

**Module 1**

**Defining and Diagnosing axSpA**

**Module 2**

**Pathogenesis, Clinical Presentation, and Disease Burden**

**Module 3**

**axSpA Disease Assessments**

**Module 4**

**axSpA Disease Management**

Module 1


# Defining and Diagnosing axSpA

# Learning Objectives



- Describe the two sub-types of axSpA disease (AS/r-axSpA and nr-axSpA).
- Differentiate between classification criteria and diagnosis.
- Describe classification criteria for AS/axSpA and nr-axSpA.
- Describe diagnosis of axSpA (AS and nr-axSpA) in clinical practice.
- Explain the challenges of diagnosis in axSpA (AS and nr-axSpA).

# axSpA Belongs to the Spectrum of Spondyloarthropathies



AS=Ankylosing Spondylitis; IBD=Inflammatory Bowel Disease; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis; SpA=Spondyloarthritis.


1. Proft F and Poddubnyy D. *Ther Adv Musculoskel Dis.* 2018;10(5-6):129-139. 2. Terenzi R, et al. *Clin Exp Rheumatol.* 2018;36(1):1-14.

# Axial Spondyloarthritis (axSpA)

**axSpA is a chronic inflammatory disease of the sacroiliac (SI) joint and axial skeleton that can progress to spinal fusion.<sup>1</sup>**

- It may also involve peripheral joints (hips, shoulders), entheses and digits, and extra-articular organs (intestines, skin, eyes, lung, and heart).<sup>1</sup>

## Early SIJ/Spine Abnormalities



- Abnormalities include inflammation, such as bone marrow edema, and small localized areas of erosion in the SIJs.<sup>2,3</sup>
- Inflammatory changes may not be obvious via x-ray. MRI is better suited to detect abnormalities.<sup>2,3</sup>

## Late SIJ/Spine Abnormalities



- Spine abnormalities include bridging syndesmophytes and fused facet joints, as well as partial or complete bone fusion of the SIJ (ankylosis).<sup>2,3</sup>
- Structural changes can be seen via x-ray.<sup>2,3</sup>

axSpA=Axial Spondyloarthritis; MRI=Magnetic Resonance Imaging; SIJ=Sacroiliac Joint.

1. van der Heijde D. In: *Primer on the Rheumatic Diseases*. 2008:193-199. 2. Van Mechelen M, et al. *Calcif Tissue Int*. 2018;102(5):547-558. 3. Østergaard M, et al. *Ther Adv Musculoskel Dis*. 2012;4(4):301-311.

# Epidemiology

# Prevalence of HLA-B27



**<10%**


Prevalence of HLA-B27 in the general population<sup>1-3</sup>



**70-90%**

Prevalence of HLA-B27 in White patients with axSpA<sup>1,3,4</sup>

## Frequency of HLA-B27 in General Worldwide Populations<sup>5</sup>



The absolute risk of axSpA in persons with HLA-B27 positivity, without a first-degree relative affected by the disease, is estimated to be **2-10%**.<sup>4</sup>

Note: The 40-50% frequency in Siberia and Alaska refer to the frequency in native Siberians and Alaskans, and not the White settlers. The <1% frequency in Australia refers to that in Australian Aborigines, and not in the White settlers.

The <1% frequency in Japan, Africa, and the 2% frequency in Brazil refer to the general population frequencies of HLA-B27 in those regions.

axSpA=Axial Spondyloarthritis; B=Black; H=Hispanic; HLA-B27=Human Leukocyte Antigen B27; W=White.

1. Walsh JA, Magrey M. *J Clin Rheumatol*. 2021;27(8):e547-e560. 2. Reveille JD, et al. *Arthritis Rheumatol*. 2012;64(5):1407-1411. 3. Sieper J, et al. *Nat Rev Dis Primers*. 2015;1:15013.

4. Taurog JD, et al. *N Engl J Med*. 2016;374(26):2563-2574. 5. [https://spondylitis.org/wp-content/uploads/2020/11/DiseaseSeverity\\_JohnReveille.pdf](https://spondylitis.org/wp-content/uploads/2020/11/DiseaseSeverity_JohnReveille.pdf) (Accessed May 2023).

# AS/r-axSpA and nr-axSpA Prevalence




**Estimated global prevalence rates:**

**0.3-1.4%**<sup>1</sup>  
axSpA

**0.1-1.4%**<sup>1</sup>  
AS/r-axSpA

**0.35-0.5%**<sup>2,3</sup>  
nr-axSpA



**r-axSpA is more common in males**, (male-to-female ratio=2:1), whereas **nr-axSpA has a more equal sex distribution**.<sup>1,2</sup>



Age of onset for majority of patients is within **the third decade of life** (<30 years).<sup>1</sup>



**Rates of progression from nr-axSpA to AS/r-axSpA:**

**2-12%**  
in 2 years<sup>4,5</sup>

**26-28%**  
after ≥10 years<sup>6</sup>

Note: Differences in study design can explain some variability in global prevalence; further, prevalence of the disease is highly affected by the background prevalence of the HLA- B27 gene.<sup>1</sup>


AS=Ankylosing Spondylitis; axSpA=Axial Spondyloarthritis; HLA-B27=Human Leukocyte Antigen-B27; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis.

1. Navarro-Compán V, et al. *Ann Rheum Dis*. 2021;80(12):1511-1521. 2. Magrey M, et al. *Medicine (Baltimore)*. 2022;101(15):e29063. 3. Reveille JD, Weisman MH. *Am J Med Sci*. 2013;345(6):431-436. 4. Ruderman E, et al. *Arthritis Rheum*. 2013;65:S1052-1053. 5. Poddubnyy D, et al. *Ann Rheum Dis*. 2011;70(8):1369-1374. 6. Ghosh N, Ruderman EM. *Arthritis Res Ther*. 2017;19(1):286. 7. Wang R, et al. *Arthritis Rheumatol*. 2016;68(6):1415-1421.



# Classification Criteria and Diagnosis

# axSpA Terminology and Classification




AS=Ankylosing Spondylitis; ASAS=Assessment of SpondyloArthritis International Society; HLA=Human Leukocyte Antigen; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis; SPARCC=Spondyloarthritis Research Consortium of Canada.

1. Saleem SN, et al. *Arthritis Rheumatol.* 2014;66(12):3311-3316. 2. Keitel W. *Z Rheumatol.* 2012;71(4):330-339. 3. Moll JM, Wright V. *Ann Rheum Dis.* 1973;32(4):354-363. 4. Reveille JD, Weisman MH. *Am J Med Sci.* 2013;345(6):431-436. 5. Schlosstein L, et al. *N Engl J Med.* 1973;288(14):704-706. 6. van der Linden S, et al. *Arthritis Rheum.* 1984;27(4):361-368. 7. Landewé RB, et al. *J Rheumatol.* 2005;32(10):2050-2055. 8. Rudwaleit M, et al. *Ann Rheum Dis.* 2009;68(6):777-783.

# AS/r-axSpA and nr-axSpA Classification

- Diagnosis and classification of AS has been based on the modified New York (mNY) criteria, which require the presence of radiographic sacroiliitis.<sup>1</sup>
- The ASAS criteria allow for the classification of patients without radiographic changes as nr-axSpA.<sup>2</sup>
  - Positive MRI may be used to identify this subtype.
  - The criteria also contains a clinical arm, which enhances the capability to identify patients without MRI findings as it requires the presence of positive HLA-B27 and two SpA features.
- The imaging arm of the ASAS classification criteria includes sacroiliitis on X-rays (as per mNY criteria) as one of its criterion and therefore, identifies patients with AS/r-axSpA.<sup>2</sup>



AS=Ankylosing Spondylitis; ASAS=Assessment of SpondyloArthritis International Society; axSpA=Axial Spondyloarthritis; HLA=Human Leukocyte Antigen; mNY=modified New York; MRI=Magnetic Resonance Imaging; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis; SpA=Spondyloarthritis.

1. van der Linden S, et al. *Arthritis Rheum.* 1984;27(4):361-368. 2. Rudwaleit M, et al. *Ann Rheum Dis.* 2009;68(6):777-783.

# Modified New York Criteria and ASAS Classification Criteria

## Modified New York Criteria<sup>1,2</sup>

### 1. Clinical criteria:<sup>1,2</sup>

- 🔍 **Low back pain** and **stiffness** for >3 months, which improves with exercise but is not relieved by rest
- 🔍 **Limitation of motion** of the lumbar spine in both sagittal and frontal planes
- 🔍 **Limitation of chest expansion** relative to normal values corrected for age and sex


### 2. Radiologic criterion:<sup>1,2</sup>

- 🔍 **Sacroiliitis** grade  $\geq 2$  bilaterally or sacroiliitis grade 3-4 unilaterally<sup>a</sup>

**Definite AS if the radiographic criterion is associated with  $\geq 1$  clinical criterion.<sup>1,2</sup>**

## ASAS Classification Criteria<sup>1</sup>

In patients with  $\geq 3$  months chronic back pain and age at onset <45 years:



nr-axSpA classification is based on a positive MRI (imaging arm) OR on clinical arm.<sup>1,2</sup>

<sup>a</sup>Sacroiliitis grading can be achieved using plain radiographs.

AS=Ankylosing Spondylitis; ASAS=Assessment of Spondyloarthritis International Society; HLA-B27=Human Leukocyte Antigen B27; MRI=Magnetic Resonance Imaging; nr-axSpA=Nonradiographic Axial Spondyloarthritis; SpA=Spondyloarthritis.

1. Rudwaleit M, et al. *Ann Rheum Dis.* 2009;68:777-783. 2. van der Linden S, et al. *Arthritis Rheum.* 1984;27:361-368.

# ASAS Classification Criteria

## SpA features:<sup>1</sup>

- Inflammatory back pain
- Arthritis
- Enthesitis (heel)
- Uveitis
- Dactylitis
- Psoriasis
- Ulcerative colitis/Crohn's disease
- Good response to NSAIDs
- Family history of SpA
- HLA-B27 positive
- Elevated CRP

## ASAS Classification Criteria<sup>1</sup>

In patients with  $\geq 3$  months chronic back pain  
and age at onset  $< 45$  years:

IMAGING ARM	CLINICAL ARM
Sacroiliitis on imaging:  Acute inflammation on MRI highly suggestive of sacroiliitis  <b>OR</b>  Definite sacroiliitis according to modified New York criteria <sup>2</sup>	<b>OR</b> HLA-B27 positive
<b>+</b> <b><math>\geq 1</math> SpA feature</b>	<b>+</b> <b><math>\geq 2</math> other SpA features</b>

nr-axSpA classification is based on a positive MRI (imaging arm)  
OR on clinical arm.<sup>1,2</sup>

ASAS=Assessment of Spondyloarthritis International Society; CRP=C-Reactive Protein; HLA-B27=Human Leukocyte Antigen B27; MRI=Magnetic Resonance Imaging; nr-axSpA=Nonradiographic Axial Spondyloarthritis; NSAID=Nonsteroidal Anti-Inflammatory Drug; SpA=Spondyloarthritis.


1. Rudwaleit M, et al. *Ann Rheum Dis*. 2009;68:777-783. 2. van der Linden S, et al. *Arthritis Rheum*.1984;27:361-368.

# axSpA: One Disease, Two Subtypes

axSpA encompasses 2 subtypes of the same disease<sup>1-3</sup>

## nr-axSpA<sup>4</sup>


No definite sacroiliitis  
according to mNY criteria



**Grade 2 or less unilaterally**  
sacroiliitis according to mNY criteria<sup>4</sup>

## AS/r-axSpA<sup>4</sup>

Definite sacroiliitis  
according to mNY criteria



**Definite**  
radiographic sacroiliitis<sup>4</sup>

AS=Ankylosing Spondylitis; axSpA=Axial Spondyloarthritis; mNY=Modified New York; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis.

1. Ward MM, et al. *Arthritis Rheumtol.* 2016;68(2):282-298. 2. Taurog JD, et al. *N Engl J Med.* 2016;374(26):2563-2574. 3. van der Linden S, et al. *Arthritis Rheum.* 1984;27(4):361-368. 4. Sieper J, et al. *Ann Rheum Dis.* 2009;68(Suppl 2):ii1-44.

# Defining AS/r-axSpA and nr-axSpA in Clinical Trials and Clinical Practice

## Clinical Practice

### Diagnosis

- AS is diagnosed based on history, physical examination, imaging findings and careful diagnostic considerations.<sup>1,2</sup>
  - Classification criteria should not be used to diagnose patients.<sup>3</sup>

### Imaging

- Most HCPs rely on imaging interpretations by radiologists and/or their own interpretation.<sup>1</sup>

## Clinical Trials

### Classification

- Patients are required to have a diagnosis and fulfill classification criteria such as the mNY and/or the ASAS criteria.<sup>2</sup>

### Imaging

- Sometimes, an expert interpretation system is used to decrease intra- and inter-reader variability and assure a more accurate diagnosis, including defined criteria to identify sacroiliitis.<sup>1,3</sup>

AS=Ankylosing Spondylitis; ASAS=Assessment of SpondyloArthritis International System; axSpA=Axial Spondyloarthritis; HCP=Health Care Practitioner; mNY=Modified New York Criteria; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis.

1. Walsh JA, Magrey M. *J Clin Rheumatol*. 2021;27(8):e547-e560. 2. Taurog JD, et al. *N Engl J Med*. 2016;374:2563-2574. 3. Danve A, et al. *Clin Rheumatol*. 2019;38:625-634.

# Defining AS/r-axSpA and nr-axSpA in Clinical Trials and Clinical Practice

Clinical Practice	Clinical Trials
Diagnosis	Classification

axSpA **lacks validated diagnostic criteria.**<sup>3</sup>

.....

Classification criteria **should not be used to make a diagnosis of axSpA** due to the potential for misclassification.<sup>3</sup>

- Most HCPs rely on imaging interpretations by radiologists and/or their own interpretation.<sup>1</sup>

variability and assure a more accurate diagnosis, including defined criteria to identify sacroiliitis.<sup>1,3</sup>

AS=Ankylosing Spondylitis; ASAS=Assessment of SpondyloArthritis International System; axSpA=Axial Spondyloarthritis; HCP=Health Care Practitioner; mNY=Modified New York Criteria; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis.

1. Walsh JA, Magrey M. *J Clin Rheumatol*. 2021;27(8):e547-e560. 2. Taurog JD, et al. *N Engl J Med*. 2016;374:2563-2574. 3. Danve A, et al. *Clin Rheumatol*. 2019;38:625-634.



# Diagnosis of axSpA in Clinical Practice

In clinical practice, diagnosis can be based on a range of different assessments and information:



Personal and family history, and physical examination.



Symptoms, such as chronic inflammatory back pain, fatigue, stiffness.



Evaluation of other causes of back pain, and differentiation between inflammatory and mechanical back pain.



Imaging including radiograph of the sacroiliac joint, in some cases also of the spine, and possibly MRIs.



Laboratory tests (e.g., HLA-B27, CRP).


**Other causes of back pain confound diagnosis.**

# Diagnosing axSpA – Recognizing the Compelling Clinical Picture

Ask questions to help differentiate IBP from mechanical back pain<sup>1</sup>

Recognize that features of axSpA may not be objective<sup>2</sup>

Use SpA features as clinical clues<sup>2</sup>




axSpA=Axial Spondyloarthritis; HLA-B27=Human Leukocyte Antigen B27; IBP=Inflammatory Back Pain; MRI=Magnetic Resonance Imaging; NSAID=Nonsteroidal Anti-Inflammatory Drug.

1. NASS. Differentiating Inflammatory and Mechanical Back Pain. April 2018. Available from: <https://nass.co.uk/wp-content/uploads/2020/03/Physiotherapy-modules-1.pdf>. (Accessed March 2023).

2. Deodhar AA. *Am J Managed Care*. 2019;25 (17, suppl):S319-S330. 3. Rudwaleit M, et al. *Ann Rheum Dis*. 2004;63(5):535-543.

# The Journey of axSpA

# The Journey to an axSpA Diagnosis




axSpA=Axial Spondyloarthritis; CRP=C-Reactive Protein; CVD=Cardiovascular Disease; DISH=Diffuse Idiopathic Skeletal Hyperostosis; ESR=Erythrocyte Sedimentation Rate; IBD=Inflammatory Bowel Disease; IBP=Inflammatory Back Pain; NSAID=Nonsteroidal Anti-inflammatory Drug; SpA=Spondyloarthritis.

1. Rudwaleit M, et al. *Ann Rheum Dis.* 2009;68:777-783. 2. Ogdie A, et al. *Rheumatol Ther.* 2019;6:255-267. 3. Danve A, et al. *Clin Rheumatol.* 2019;38:625-634. 4. Walsh JA, Magrey M. *J Clin Rheumatol.* 2021;27(8):e547-e560.

5. Voirin-Hertz M, et al. *Semin Arthritis Rheum.* 2020;50(1):48-53. 6. Moltó A, et al. *Best Pract Res Clin Rheumatol.* 2018;32(3):390-400. 7. Strand VC, et al. *J Clin Rheumatol.* 2017;23(7):383-391.

8. Lapane KL, et al. *BMC Fam Pract.* 2021;22(1):251. 9. Zhao SS, et al. *Rheumatology (Oxford).* 2021;60(4):1620-1628. 10. Carvalho PD and Machado PM. *Best Pract Res Clin Rheumatol.* 2019;33(4):101427.


# Natural History of axSpA<sup>1</sup>



AS=Ankylosing Spondylitis; axSpA=Axial Spondyloarthritis; CRP=C-Reactive Protein; HLA-B27=Human Leukocyte Antigen B27; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis; SIJ=Sacroiliac Joint; US=United States.

1. Garg N, et al. *Best Pract Res Clin Rheumatol*. 2014;28:663-672. 2. Deodhar A, et al. *Lancet*. 2020;395:53-64. 3. Ruderman E, et al. *Arthritis Rheum*. 2013;65:S1052-1053. 4. Poddubnyy D, et al. *Ann Rheum Dis*. 2011;70(8):1369-1374. 5. Ghosh N, Ruderman EM. *Arthritis Res Ther*. 2017;19(1):286. 6. Wang R, et al. *Arthritis Rheumatol*. 2016;68(6):1415-1421. 7. Poddubnyy D, et al. *Ann Rheum Dis*. 2022;81:96-97. Abstract OP0149. 8. Nikiphorou E, et al. *Curr Rheumatol Rep*. 2020;22(9):55. 9. Nikiphorou E, et al. *Arthritis Rheumatol*. 2020;72(11):1855-1862.


# Delays in Diagnosis Add to the High Disease Burden




Average time from onset of symptoms to a diagnosis of axSpA

**6.5-10 years<sup>1-3</sup>**

A delayed diagnosis of axSpA is associated with:<sup>1,2,4</sup>



Greater radiographic progression



Reduced response to treatment



Worse physical function




Poorer quality of life

axSpA=Axial Spondyloarthritis.

1. Lapane KL, et al. *BMC Fam Pract*. 2021;22(1):251. 2. Zhao SS, et al. *Rheumatology (Oxford)*. 2021;60(4):1620-1628. 3. Carvalho PD and Machado PM. *Best Pract Res Clin Rheumatol*. 2019;33(4):101427.

4. Yi E, et al. *Rheumatol Ther*. 2020;7(1):65-87.

# Challenges in Diagnosing axSpA



axSpA=Axial Spondyloarthritis; CRP=C-reactive Protein; ESR=Erythrocyte Sedimentation Rate; HCP=Healthcare Professional; HLA-B27=Human Leukocyte Antigen B27; IBP=Inflammatory Back Pain; MRI=Magnetic Resonance Imaging; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis.

1. Danve A, Deodhar A. *Clin Rheumatol*. 2019;38:625-634.
2. Poddubnyy D, et al. *RMD Open*. 2018;4:e000825.
3. Reveille JD. *Clin Rheumatol*. 2015;34(6):1009-1018.
4. Danve A, O'Dell J. *Int J Rheum Dis*. 2015;18(8):826-834.
5. Rusman T, et al. *Rheumatology (Oxford)*. 2020;59(Suppl. 4):iv38-iv46.
6. Lapane KL, et al. *BMC Fam Pract*. 2021;22(1):251.
7. Sieper J, et al. *Ann Rheum Dis*. 2002;61 Suppl 3(Suppl 3):iii8-iii18.
8. Deodhar A, et al. *Arthritis Rheumatol*. 2016;68(7):1699-1676.
9. Aggarwal R, et al. *Arthritis Care Res (Hoboken)*. 2015;67(7):891-897.


# Differentiating IBP from Mechanical Back Pain

**13%**

of adults in the US have chronic back pain.<sup>1</sup>

**5%**

of patients with chronic back pain are estimated to have axSpA.<sup>2</sup>



**5%-15%** and **28%-35%**

of patients with acute and chronic back pain, respectively, are reported to have IBP.<sup>2</sup>

**14%-16%**

of patients with IBP are estimated to have axSpA.<sup>2</sup>

## IBP Symptoms<sup>2</sup>

Insidious onset of back pain.

---

Morning stiffness in the lower back.

---

Improvement of back pain with exercise but not with rest.

---

Awakening at night or early morning because of back pain.

---

Alternating buttock pain.

---

axSpA=Axial Spondyloarthritis; IBP=Inflammatory Back Pain; US=United States.

1. Danve A, Deodhar A. *Clin Rheumatol*. 2019;38:625-634. 2. Poddubnyy D, et al. *RMD Open*. 2018;4:e000825.



# Common Mimickers of axSpA

## Fibromyalgia


Pooled prevalence is 16% in patients with axSpA.<sup>1</sup>

Clinical overlap exists with chronic nocturnal back pain, morning stiffness, disturbed sleep, and fatigue.<sup>2</sup>

Increased clinical vigilance is needed for underlying axSpA in patients treated for fibromyalgia.<sup>2</sup>

## Mechanical back pain

Clinicians may be unfamiliar with symptoms of back pain specific to axSpA (age of onset, extra-articular manifestations).<sup>3</sup>



## Other

Lumbar scoliosis<sup>4</sup>

Diffuse idiopathic skeletal hyperostosis (DISH)<sup>5</sup>

Misread MRI (pregnancy/postpartum,<sup>6</sup> athletes<sup>6</sup>)

Osteoarthritis<sup>7</sup>


Anxiety/depression-related back pain<sup>7</sup>

Sciatica<sup>7</sup>

axSpA=Axial Spondyloarthritis; MRI=Magnetic Resonance Imaging.

1. Zhao SS, et al. *Best Pract Res Clin Rheumatol*. 2019;33(3):1014-23.
2. Ablin JN, et al. *Arthritis Care Res (Hoboken)*. 2017;69(5):724-729.
3. Danve A, et al. *Clin Rheumatol*. 2019;38:625-634.
4. Voirin-Hertz M, et al. *Semin Arthritis Rheum*. 2020;50(1):48-53.
5. Vaishya R, et al. *J Clin Orthop Trauma*. 2017;8(2):191-196.
6. de Winter J, et al. *Arthritis Rheumatol*. 2018;70(7):1042-1048.
7. Ogdie A, et al. *Rheumatol Ther*. 2019;6:255-267.

# Common Clues in axSpA Diagnosis – What to Look for?



axSpA=Axial Spondyloarthritis; IBD=Inflammatory Bowel Disease; NSAID=Non-steroidal Anti-inflammatory Drug; PsA=Psoriatic Arthritis; PsO=Psoriasis; SpA=Spondyloarthritis.

1. McGonagle D, et al. *Semin Arthritis Rheum.* 2021;51(6):1147-1161. 2. Walsh JA, Magrey M. *J Clin Rheumatol.* 2021;27(8):e547-e560. 3. Rudwaleit M, et al. *Ann Rheum Dis.* 2009;68(6):777-783.

4. Winkler AE, Miller M. *Mo Med.* 2022;119(1):79-83.

# Summary



- axSpA refers to the **inflammation of the axial skeleton** and encompasses **two subtypes**: AS/r-axSpA and nr-axSpA.<sup>1-4</sup>
  - nr-axSpA is defined as patients without changes consistent with sacroiliitis that meets mNY criteria.<sup>4</sup>
  - r-axSpA is defined as definite sacroiliitis according to mNY criteria, plus at least one SpA feature if we are going to use ASAS criteria.<sup>4</sup>
- **Diagnosis can be challenging** with multiple factors contributing to delays, particularly in patients presenting with less definitive clinical features.<sup>5-13</sup>
- **Classification criteria** are used to identify eligible patients for clinical trial enrollment and are **not intended to be used to diagnose patients.**<sup>5,13</sup>

AS=Ankylosing Spondylitis; axSpA=Axial Spondyloarthritis; mNY=modified New York; nr-axSpA=Nonradiographic Axial Spondyloarthritis; r-axSpA=Radiographic Axial Spondyloarthritis.

1. Ward MM, et al. *Arthritis Rheumatol.* 2016;68(2):282-298. 2. Taurog JD, et al. *N Engl J Med.* 2016;374(26):2563-2574. 3. van der Linden S, et al. *Arthritis Rheum.* 1984;27(4):361-368. 4. Sieper J, et al. *Ann Rheum Dis.* 2009;68(Suppl 2):ii1-44. 5. Danve A, Deodhar A. *Clin Rheumatol.* 2019;38:625-634. 6. Poddubnyy D, et al. *RMD Open.* 2018;4:e000825. 7. Reveille JD. *Clin Rheumatol.* 2015;34(6):1009-1018. 8. Danve A, O'Dell J. *Int J Rheum Dis.* 2015;18(8):826-834. 9. Rusman T, et al. *Rheumatology (Oxford).* 2020;59(Suppl. 4):iv38-iv46. 10. Lapane KL, et al. *BMC Fam Pract.* 2021;22(1):251. 11. Sieper J, et al. *Ann Rheum Dis.* 2002;61 Suppl 3(Suppl 3):iii8-iii18. 12. Deodhar A, et al. *Arthritis Rheumatol.* 2016;68(7):1699-1676. 13. Aggarwal R, et al. *Arthritis Care Res (Hoboken).* 2015;67(7):891-897.

# US Medical Education

**For additional resources on axSpA, scan the code**

